STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting down
The shutdown poses a critical setback for the biopharma sector's high-profile push to repurpose oncology cell therapies for autoimmune diseases, likely prompting intensified regulatory scrutiny and clinical protocol reassessments across peer pipelines.
STAT News·